Telepharmacy for outpatients with cancer: An implementation evaluation of videoconsults compared to telephone consults using the CFIR 2.0
- PMID: 39308557
- PMCID: PMC11415766
- DOI: 10.1016/j.rcsop.2024.100501
Telepharmacy for outpatients with cancer: An implementation evaluation of videoconsults compared to telephone consults using the CFIR 2.0
Abstract
Background: Medication history telepharmacy consults are conducted prior to patients commencing their systemic anti-cancer therapy. At the study institution, this has historically been carried out as an unscheduled telephone consult. However, due to challenges with telephone consults, a scheduled videoconsult model was established. Funding, time efficiency, and completion rate for videoconsults compared to telephone consults have been examined previously.
Objective: The aim of this study was to determine staff perceptions of the factors that influence implementation, including enablers and barriers, for videoconsults compared to telephone consults, to inform model sustainability.
Methods: Semi-structured interviews were conducted with staff (n = 14) involved with the videoconsult service, or who provided care for patients who had a videoconsult. Interviews were coded for positive or negative influence and strength using the Consolidated Framework for Implementation Research (CFIR) 2.0, to understand which constructs influence implementation.
Results: Thirty-nine of the 79 constructs, from across four domains were identified as influences for the telephone and videoconsult models. Six constructs were strongly differentiating for videoconsults over telephone consults. Of the 25 positively influencing constructs for the videoconsult model, strongest ratings (+2) were given for innovation advantages, critical incidents, support persons assisting in the consult, financing related to funding reimbursement, and telehealth coordinator capability and motivation. Barriers unique to the videoconsult model included the many steps that were involved, compatibility with workflows, and pharmacist resource. Similarities and differences unique to each model were identified.
Conclusion: Findings demonstrated a number of strongly differentiating constructs highlighting superiority of the videoconsult model. However, implementation of both models had multiple enablers and barriers that may influence adoption. The potential of a hybrid service, using both telephone consults and videoconsults, may help optimise delivery of services.
Keywords: Cancer pharmacist; Oncology pharmacist; Telehealth; Telepharmacy; Telephone; Video call; Videoconsult.
© 2024 The Authors. Published by Elsevier Inc.
Conflict of interest statement
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
A systematic review of synchronous telepharmacy service models for adult outpatients with cancer.Res Social Adm Pharm. 2024 Jun;20(6):25-33. doi: 10.1016/j.sapharm.2024.02.016. Epub 2024 Mar 2. Res Social Adm Pharm. 2024. PMID: 38490859
-
Changing from telephone to videoconference for pre-treatment pharmacist consults in cancer services: Impacts to funding and time efficiency.J Telemed Telecare. 2021 Dec;27(10):680-684. doi: 10.1177/1357633X211048393. J Telemed Telecare. 2021. PMID: 34726996
-
An evaluation of telephone versus videoconference consults for pre-treatment medication history taking by cancer pharmacists.J Telemed Telecare. 2022 Dec;28(10):750-756. doi: 10.1177/1357633X221122140. J Telemed Telecare. 2022. PMID: 36346932
-
Exploring factors of uneven use of telehealth among outpatient pharmacy clinics during COVID-19: A multi-method study.Res Social Adm Pharm. 2022 Sep;18(9):3602-3611. doi: 10.1016/j.sapharm.2022.02.003. Epub 2022 Feb 9. Res Social Adm Pharm. 2022. PMID: 35183460 Free PMC article.
-
Barriers and enablers to the implementation of healthy lifestyle interventions for people with disability living in supported accommodation: A systematic review using the consolidated framework for implementation research.Disabil Health J. 2023 Apr;16(2):101442. doi: 10.1016/j.dhjo.2023.101442. Epub 2023 Jan 16. Disabil Health J. 2023. PMID: 36740546
References
-
- Cancer Therapy Medication Safety Working Group COSA guidelines for the safe prescribing, dispensing and administration of systemic cancer therapy. 2017. https://app.magicapp.org/#/guideline/n3QAOj Accessed 08/08/2024.
-
- Coutsouvelis J., Adams J., Bortz H., et al. Standard of practice in oncology and haematology for pharmacy services. J Pharm Pract Res. 2020;50(6):528–545. doi: 10.1002/jppr.1686. - DOI
-
- Australian Commission on Safety and Quality in Health Care . ACSQHC; Sydney: 2011. Patient Centred Care: Improving Quality and Safety through Partnerships with Patients and Consumers.https://www.safetyandquality.gov.au/sites/default/files/migrated/PCCC-Di... Accessed 08/08/2024.
LinkOut - more resources
Full Text Sources
Miscellaneous